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Abstract
Peroxisome biogenesis disorders (PBD) are classified into Zellweger syndrome (ZS), infantile Refsum disease (IRD) and
neonatal adrenoleukodystrophy. Disturbances in the differentiation of neural cells such as migration arrest are characteristic
of PBD. So far the pathogenesis of these disturbances is not clearly understood. We describe an altered metabolism of
glycosphingolipids in PBD which has not yet been investigated. We observed an increased amount of a-series gangliosides,
GM2, GM1 and GD1a, in the fibroblasts of patients with ZS and IRD. Gangliosides GM1 and GD1a were not present in
detectable amounts in normal subjects. A key step in the synthesis of a-series gangliosides is a transfer of GalNAc to
ganglioside GM3, so we determined the level of ganglioside GM3 by immunohistochemical methods. We found a granular
structure, which was positive toward anti-ganglioside GM3 antibody in the cytoplasm of the patients’ fibroblasts. In control
cells, the cell membrane was slightly positive toward anti-GM3 antibody. These results may help to clarify the pathogenesis
of PBD with respect to the functional roles of glycosphingolipids in cell differentiation, proliferation and apoptosis. ß 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction
Peroxisome biogenesis disorders (PBD) are charac-
terized by a dysfunction in the formation of peroxi-
somes. Zellweger syndrome (ZS) is the most severe
form of PBD, in which peroxisomes are entirely ab-
sent. There are numerous biochemical abnormalities,
such as an accumulation of very long free fatty acids,
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Abbreviations: CMH, ceramide monohexoside, GlcL1-1PCer; CDH, ceramide dihexoside, GalL1-4GlcL1-1PCer; CTH, ceramide tri-
hexoside, GalK1-4GalL1-4GlcL1-1PCer; GM3, ganglioside GM3, NeuAcK2-3GalL1-4GlcL1-1PCer; GM2, ganglioside GM2, GalNAcL1-
4Gal(3-2NeuAcK2)L1-4GlcL1-1PCer; GM1, ganglioside GM1, GalL1-3GalNAcL1-4Gal(3-2NeuAcK2)L1-4GlcL1-1PCer; GD1a, ganglio-
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and a decrease in plasmalogen levels in patients with
ZS [1]. Infantile Refsum disease (IRD), the mildest
form of PBD, is also characterized by the absence of
peroxisomes and the presence of biochemical abnor-
malities. Pathologically, various migration anoma-
lies, such as polymicrogyria and a heterotropic gray
matter, were reported in the brains of patients with
ZS and ZS model mice [2^7]. Although the exact
mechanism underlying these pathological changes in
the central nervous system (CNS) is as yet unknown,
Evrard et al. suggested the possibility of toxicity of a
PAS-positive inclusion body to developing neural tis-
sues in the CNS of patients with ZS [3]. The inclu-
sion body was likely to be composed of abnormal
gangliosides although it was not accurately identi¢ed
[8].
The functional roles of glycosphingolipids in cell
growth, di¡erentiation, proliferation and cell recog-
nition have been clari¢ed in recent years [9,10]. In the
developing CNS, glycosphingolipids such as ceram-
ide monohexoside (CMH) and gangliosides play an
important role in neural cell di¡erentiation [11^13].
Therefore, the analysis of the glycosphingolipid com-
position of peroxisome-de¢cient cells may help to
understand the pathogenesis of PBD. Previously,
we analyzed the glycolipid composition of model
cells (Z65) which were derived from wild Chinese
hamster ovary cells (CHO-K1 cells) with a mutagen,
ethyl methanesulfonate, and exhibited defective per-
oxisomal biogenesis. We observed the accumulation
of CMH and ganglioside GM3 in Z65 cells [14]. The
purpose of the present study was to investigate the
changes in glycosphingolipid metabolism in peroxi-
some-de¢cient cells of PBD patients. Thus, the gly-
colipid composition and localization of ganglioside
GM3 in ¢broblasts from patients with ZS and IRD
were examined.
2. Patients and methods
2.1. Patients
Patient F-04 presented classical features of ZS, i.e.,
the patient manifested craniofacial dysmorphism,
cardiopathy, hepatosplenomegaly and a typical clin-
ical course. Patient F-04 had an accumulation of
very long chain fatty acids (VLCFA) in the fatty
acid moiety of serum sphingomyelin and had no per-
oxisomes in the skin ¢broblasts. Patient F-04 died of
heart failure at 3 months old. Patient F-05 presented
at 1 year of age with delayed developmental mile-
stones and extreme joint laxity. Later, retinal pig-
mentation was found and biochemical investigations
showed an accumulation of VLCFA. A diagnosis of
IRD was made and she died at 3 years of age follow-
ing an episode of bronchiolitis. Both patients carried
the PEX2 gene mutation. The details of the mutation
analysis of the PEX2 gene in both patients were pre-
viously reported by one of the authors (N.S.) [15,16].
Control subjects (C1 and C2) of normal individuals
aged 3 months and 1 month, respectively, were ob-
tained from the cell bank (Riken Cell Bank, Japan).
2.2. Lipid extraction and thin layer chromatography
(TLC)
Fibroblasts from patients F-04 and F-05 were cul-
tured in K minimal essential medium supplemented
with 10% fetal calf serum in 5% CO2. After the ¢-
broblasts were harvested, they were lyophilized. To-
tal lipids were extracted from the ¢broblasts succes-
sively with 2 ml of chloroform/methanol/water
solution (1:1:0, 10:20:1, 20:10:1, v/v) at 40‡C for
20 min. The combined crude lipids were fractionated
into neutral and acidic portions using DEAE-Sepha-
dex (A-25, acetate form). Isolation of neutral glyco-
sphingolipids by acetylation and Florisil column
chromatography was carried out according to the
methods previously reported [14]. The puri¢ed acidic
and neutral glycosphingolipids were applied on each
glass-coated TLC plate (Silica gel 60, Merck, Ger-
many). Both fractions were developed with chloro-
form/methanol/water (55:45:10, v/v). The spots were
located by spraying with orcinol^H2SO4 reagent. The
mobilities on TLC of individual glycolipids were
compared with those of standard glycolipids. The
densities of the spots were quanti¢ed at 500 nm
with a dual-wavelength TLC densitometer (CS-
9000, Shimadzu Co., Kyoto, Japan). The standard
curve was linear from 0.1 to 1.5 Wg of each standard
glycolipid. Furthermore, we attempted to identify
each lipid by TLC immunostaining according to
the methods previously reported [17]. Brie£y, acidic
lipids were applied on a plastic plate (Sigma, St.
Louis, MO, USA) with chloroform/methanol/water
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(55:45:10, v/v). After overnight incubation of the
plates with blocking bu¡er at 4‡C, the plates were
incubated with rabbit polyclonal anti-asialoGM1
(GA1), anti-asialoGM2 (GA2), anti-gangliosides
GM1 and mouse monoclonal anti-ganglioside GM2
(YHD06) antibodies as the ¢rst antibodies. Polyclon-
al antibodies exhibiting monospeci¢city toward the
carbohydrate moieties of GA1, GA2 and GM1
were prepared by immunizing rabbits and YHD06
antibodies were generated by the conventional pro-
cedure by one of the authors (M.I.) [18]. After wash-
ing and re-incubation with blocking bu¡er, the ¢rst
antibodies bound on the plates were detected using
4-chloro-1-naphthol and H2O2 with a peroxidase-
conjugated goat anti-mouse or anti-rabbit IgM+G
(H+L) antibody (Jackson Immuno Research Labs.,
Westgrove, PA, USA).
2.3. Structural characterization of acidic lipids by
negative ion fast atom bombardment mass
spectrometry (FAB-MS)
Further identi¢cation of acidic glycolipids was per-
formed by negative ion FAB-MS, as follows. The
individual gangliosides were puri¢ed by high per-
formance liquid chromatography with Iatrobeads
(Iatron Lab, 6RB-8010, Tokyo, Japan), and the elu-
tion was carried out with chloroform/methanol/water
(55:45:2, v/v). About 5 Wg of the puri¢ed lipid from
¢broblasts of patient F-05 in 5 Wl of chloroform/
methanol (1:1, v/v) was mixed with 5 Wl of trietha-
nolamine, and the resultant mixture was put on a
stainless steel sample holder of FAB-MS. Analysis
was performed by bombardment with a neutral xe-
non beam, with a kinetic energy of 4 keV, and de-
tection of the negative ion using a mass spectrometer
(JMS HX-110; Jeol, Tokyo, Japan). Per£uoroalkyl
phosphazine was used as the mass marker.
2.4. Immunohistochemical staining of ¢broblasts of
PBD patients with anti-ganglioside GM3
antibody
The expression of ganglioside GM3 in ¢broblasts
of patients with PBD was immunohistochemically
analyzed by indirect immunoperoxidase staining
with a Vectastain ABC Kit (Vector Lab., Burlin-
game, CA, USA). Fibroblasts were cultured directly
on a glass slide with a chamber. When the subcon-
£uent stage (70% of the glass slide) was reached, the
culture medium was removed, and the cells were
washed twice with phosphate-bu¡ered saline (PBS).
Then the chamber was removed and the glass slide
was immersed in acetone at 4‡C for 5 min. After the
cells were washed with PBS, they were incubated
with anti-mouse ganglioside GM3 antibody (M-
2590, obtained from Seikagaku-kougyou, Tokyo, Ja-
pan). Then, they were incubated with biotinylated
second antibodies (Vector Lab., Burlingame, CA,
USA) and avidin-conjugated peroxidase. Labelled
gangliosides GM3 were visualized with 0.02% diami-
nobenzidine and 0.005% hydrogen peroxide in 0.05
M Tris bu¡er (pH 7.6). The nuclei were also stained
with hematoxylin.
3. Results
3.1. Glycolipids puri¢ed from the ¢broblasts of
patients with PBD
Fig. 1 shows the TLC analyses of neutral (A) and
acidic (B) glycolipids from the ¢broblasts of patient
F-04 with ZS and patient F-05 with IRD and those
from ¢broblasts (C1 and C2) of normal controls. The
position of glycolipids migrating on a TLC plate was
compared with those of standards. In the case of
neutral glycolipids, CMH, ceramide dihexoside
(CDH), ceramide trihexoside (CTH) and globoside
(Gb4Cer) were detected. Although the amount of
Table 1
Neutral and acidic glycolipid compositions in the ¢broblasts of
normal controls and the patients with PBD
C1 C2 F-04 F-05
GlcCer 0.20 0.34 0.22 0.22
LacCer 0.29 0.29 0.58 0.48
Gb3Cer 1.55 1.60 1.61 2.79
Gb4Cer 0.78 0.70 0.79 0.82
GM3 1.81 1.95 2.52 2.18
GM2 0.03 0.01 0.20 0.10
GM1 tr tr 0.08 0.12
GD3 0.15 0.20 0.11 0.43
GD1a tr tr 0.09 0.09
Values are Wg/mg dry weight of each glycolipid in the ¢bro-
blasts of controls (C1, C2), the patient with ZS (F-04) and the
patient with IRD (F-05). tr = trace.
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CDH increased slightly in the PBD patients, no sig-
ni¢cant di¡erences in the concentration of neutral
glycolipids were observed between the patients and
controls (Table 1). In the case of acidic glycolipids,
the amounts of gangliosides GM2, GM1 and GD1a
were increased in patients with PBD. The amounts of
GM2 in patients were about 6^10-fold higher than in
the controls. The amount of ganglioside GD3 in pa-
tient F-05 with IRD was about twice higher than
that in the controls. Gangliosides GM1 and GD1a
Fig. 1. TLC of neutral (A) and acidic (B) glycolipids extracted from ¢broblasts of patients with PBD and normal controls. Crude lip-
ids were fractionated into neutral and acidic glycolipids. Both fractions were developed with chloroform/methanol/water (55:45:10,
v/v) and detected using orcinol^H2SO4 reagent. (A) In both normal controls and patients, CMH, CDH, CTH and Gb4Cer were de-
tected. The amount of CDH slightly increased in the PBD patients (see Table 1). Fs, Forssman glycolipids. (B) In patients, ganglio-
sides GM2, GM1 and GD1a increased signi¢cantly. The band indicated by the arrow was identi¢ed as GD3 in another experiment.
St, glycolipids standards; C1 and C2, normal control ; F-04 and F-05, derived from patients with ZS and IRD, respectively. (C) Den-
sitometric scanning patterns of the acidic glycolipids from the normal controls and PBD patients. The peaks corresponding to the in-
creased ganglioside levels are indicated.
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were not detected in control cells, which contained
gangliosides GM3 and GD3 with a shorter carbohy-
drate chain. On the other hand, synthesis of a-series
gangliosides, i.e., GM2, GM1 and GD1a, was signif-
icantly accelerated in the PBD patients. Further
characterization of gangliosides GM2, GM1 and
GD1a was carried out as follows.
3.2. TLC immunostaining assay
Fig. 2 shows the TLC immunostaining analysis
using anti-ganglioside GM2 (A) and the anti-ganglio-
side GM1 (B) antibodies. Bands that were positively
stained with anti-ganglioside GM2 antibody were
found in both the PBD patients and normal controls.
Fig. 2. TLC immunostaining of acidic lipids with anti-ganglioside GM2 (A) and GM1 (B) antibodies. (A) In both normal controls
and PBD patients, immunoreactive fractions were detected. The amount of ganglioside GM2 was increased in the PBD patients.
(B) No fraction immunoreactive with anti-ganglioside GM1 was found in the normal controls. Ganglioside GM1 was detected only in
the PBD patients.
Fig. 3. Negative ion FAB-MS spectrum of GD1a isolated from ¢broblasts of patient F-05 with IRD. About 5 Wg of GD1a was ana-
lyzed using FAB-MS with triethanolamine as a matrix.
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The concentration of ganglioside GM2 in the PBD
patients was higher than that in the controls. There
was no band immunoreactive with anti-GM1 anti-
body in the normal controls. It was revealed that
the concentrations of gangliosides GM2 and GM1
increased in PBD patients with the speci¢c antibod-
ies. There was no band immunoreactive with anti-
GA1 and anti-GA2 antibodies in both normal con-
trols and PBD patients (data not shown).
3.3. Negative ion FAB-MS of acidic lipids
Negative ion FAB-MS spectrum of GD1a isolated
from ¢broblasts of PBD patient F-05 is shown in
Fig. 3. Negative ion FAB-MS yielded the molecular
ions [M3H]3 at m/z 1807 and m/z 1891, and the
fragment ions corresponding to the sequential cleav-
age at glycosidic linkages were [ceramide]3, [CMH]3,
[CDH]3, [GM3]3, [GM2]3 and [GM1]3, indicating
that the ganglioside was GD1a and the ions at m/z
1807 and m/z 1891 were due to the di¡erence in fatty
acid composition, corresponding to lignoceric and
stearic acids, respectively. Further characterization
of GD1a was done by TLC immunostaining with
anti-GM1 antibody after treatment of the TLC plate
with Vibrio cholerae neuraminidase at 37‡C for 2 h
(data not shown). Thus ¢broblasts from the PBD
patients were proven to express gangliosides GM2,
GM1 and GD1a, that is, a-series gangliosides. Since
the transfer of GalNAc to ganglioside GM3 initiates
the synthetic pathway of a-series gangliosides, we
then examined its expression in the cells by immuno-
histochemical staining with anti-ganglioside GM3
antibody.
3.4. Immunohistochemical staining with anti-
ganglioside GM3 antibody of the ¢broblasts from
the patients with PBD
Fig. 4 shows ¢broblasts of control (A), patient
F-04 (B) and patient F-05 (C) stained with anti-gan-
glioside GM3 antibody. In control cells, the cell
membrane was slightly positive toward anti-ganglio-
side GM3 antibody. On the other hand, the granular
structure inside the ¢broblasts from the PBD patients
was strongly stained with the antibody.
Fig. 4. Immunocytochemical characterization of ¢broblasts using anti-ganglioside GM3 antibody. (A) Fibroblasts of the normal con-
trol. (B) Fibroblasts of the ZS patient (F-04). (C) Fibroblasts of the IRD patient (F-05). Fibroblasts were stained by the anti-ganglio-
side GM3 antibody indicating the presence of ganglioside. Note the accumulation of granular ganglioside GM3 in the cytoplasm of
PBD patients. Bar indicates 50 Wm.
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4. Discussion
One of the characteristic ¢ndings in the CNS of
PBD patients is an impaired neuronal migration.
Powers [8] reported that focal losses of the cortical
radial pattern associated with micropolygyric ripples,
thin cortical plates and subcortical heterotopia can
be identi¢ed in an a¡ected fetus at 14^24 weeks ges-
tation. These ¢ndings were associated with abnormal
lipid inclusions at the ultrastructural level. Astro-
cytes, brain macrophages, meningeal, interstitial tes-
ticular, adrenocortical and renal tubular cells also
display cytoplasmic accumulation of an electron-
opaque slightly lamellated structure [19]. The chem-
ical nature of these inclusions is as yet unknown, but
they are speculated to represent abnormal ganglio-
side [8]. To our knowledge, the present study is the
¢rst description of an increase in ganglioside levels in
the ¢broblasts of PBD patients. Although much at-
tention has been paid to the pathogenic role of
VLCFA accumulation in PBD, little has been given
to the behavior of glycolipids in PBD. Glycosphin-
golipids are abundant in the CNS. Among this lipid
family, gangliosides are the most abundant particu-
larly in the mammalian CNS and display a charac-
teristic distribution pattern [20,21]. Their component
levels change during development. At gestation week
10, b-series gangliosides are the dominant ganglio-
sides, with the major ganglioside being GT1b, con-
tributing 40% of the total ganglioside sialic acid. The
proportion of ganglioside GD1a, which belongs to
the a-series gangliosides, begins to increase around
gestation week 12 [22]. These lipids are believed
to participate in various neuronal events, including
di¡erentiation and survival, signal transduction, syn-
aptic transmission and neural plasticity [13]. There-
fore, the appropriate regulation of ganglioside syn-
thesis is thought to be important at various
developmental phases in the CNS. In this study, we
found increased levels of gangliosides of the a-series,
i.e., ganglioside GM2, GM1 and GD1a. Ganglioside
GM2 accumulates in the CNS of patients with Tay^
Sachs and Sandho¡ diseases. Apoptotic neuronal
death in mouse models of this GM2 gangliosidosis
has been reported, and the accumulated ganglioside
GM2 or a derivative is suggested to trigger the apo-
ptotic cascade [23]. Ganglioside GD1a is restricted to
Purkinje cells in the cerebellum and associated with
dendrite growth and survival of Purkinje cells [24,25].
Those observations imply that the accumulation of
gangliosides in PBD is associated with the patholog-
ical cause of PBD. In general, the distribution pat-
terns of gangliosides are di¡erent between various
tissues. In the CNS, the amount of gangliosides is
much higher than that in ¢broblasts and gangliosides
of more complicated structures are contained in the
CNS [26,27]. It seems that the change in ganglioside
composition in the CNS of PBD patients is more
signi¢cant and complicated than that in ¢broblasts.
The analysis of glycolipid composition in the CNS of
patients with PBD is required to con¢rm it.
It has not been identi¢ed whether the accumula-
tion of glycosphingolipids is a result of primary per-
oxisomal dysfunction or that of a secondary event
followed by metabolic abnormalities such as VLCFA
accumulation and plasmalogen de¢ciency. Previ-
ously, we demonstrated the increased incorporation
of [3-14C]serine into sphingolipids and the accumula-
tion of CMH and GM3 in peroxisome-de¢cient
Z65 cells [14]. We also measured the metabolic
rate of glycosphingolipids using [3-14C]serine as a
tracer in patients’ ¢broblasts. The incorporation of
[3-14C]serine to phosphatidylserine, phosphatidyleth-
anolamine and sphingomyelin in the patients’ ¢bro-
blasts was greater than that in normal subjects in
addition to an accelerated metabolic rate of CMH
(data not shown). The expression of ceramide gluco-
syltransferase, which catalyzes the ¢rst glycosylation
step of glycosphingolipid synthesis, increased in
Z65 cells compared with that in control CHO-K1
cells (in preparation). In PBD patients, the activities
of sialyltransferase and N-acetylgalactosaminyltrans-
ferase, which are involved in the synthesis of a-series
gangliosides, are expected to enhance the activity.
In our next study we will investigate the relation
between peroxisomal dysfunction and the accelera-
tion of ganglioside synthesis in peroxisome-de¢cient
cells.
In conclusion, we demonstrated the accumulation
of a-series gangliosides in ¢broblasts of patients with
PBD due to the PEX2 gene mutation. This ¢nding
may help to elucidate the pathogenesis of impaired
neuronal cell migration and other abnormalities in
the CNS of patients with PBD.
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